Is Sandu Pharmaceuticals a good stock to invest in?

Sandu Pharmaceuticals can be analyzed on the following key metrics - TTM P/E: 14.73 Sector P/E: 45.09 Dividend Yield: 1.6% D/E ratio: -

Sandu Pharmaceuticals Share Price

Sector: Biotechnology & Drugs

Powered by

49.80 -0.41 (-0.82%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 49.60

Today’s High 51.50

52 Week Low 43.75

52 Week High 69.50

Key Metrics

Market Cap (In Cr) 48.18
Beta 0.69
Div. Yield (%) 1.6
P/B 1.15
TTM P/E 14.73
Sector P/E 45.09
D/E 0
Open Price 50.5
Prev Close 50.21

View All Metrics

Sandu Pharmaceuticals Analysis

Price Analysis

1 Week

-1.03%
3 Months

2.02%
6 Month

-11.38%
YTD

-12.71%
1 Year

-13.99%

Risk Meter

40% Low risk
40% Moderate risk
40% Balanced Risk
40% High risk
40% Extreme risk

Sandu Pharmaceuticals Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2025

Total Revenue
67.19

Selling/ General/ Admin Expenses Total
10.92

Depreciation/ Amortization
0.67

Other Operating Expenses Total
21.41

Total Operating Expense
65.1

Operating Income
2.09

Net Income Before Taxes
2.16

Net Income
1.55

Diluted Normalized EPS
1.6

Period
2024

Total Revenue
67.28

Selling/ General/ Admin Expenses Total
10.07

Depreciation/ Amortization
0.58

Other Operating Expenses Total
22.34

Total Operating Expense
65.57

Operating Income
1.71

Net Income Before Taxes
2.07

Net Income
1.46

Diluted Normalized EPS
1.51

Period
2023

Total Revenue
65.35

Selling/ General/ Admin Expenses Total
11.1

Depreciation/ Amortization
0.52

Other Operating Expenses Total
20.58

Total Operating Expense
63.38

Operating Income
1.97

Net Income Before Taxes
2.22

Net Income
1.52

Diluted Normalized EPS
1.61

Period
2022

Total Revenue
65.5

Selling/ General/ Admin Expenses Total
8.91

Depreciation/ Amortization
0.53

Other Operating Expenses Total
17.97

Total Operating Expense
63.16

Operating Income
2.34

Net Income Before Taxes
2.32

Net Income
1.59

Diluted Normalized EPS
1.87

Period
2021

Total Revenue
58.76

Selling/ General/ Admin Expenses Total
8.14

Depreciation/ Amortization
0.56

Other Operating Expenses Total
13.95

Total Operating Expense
57.15

Operating Income
1.6

Net Income Before Taxes
1.68

Net Income
1.09

Diluted Normalized EPS
1.54

Period
2020

Total Revenue
48.37

Selling/ General/ Admin Expenses Total
6.85

Depreciation/ Amortization
0.55

Other Operating Expenses Total
14.95

Total Operating Expense
47.47

Operating Income
0.9

Net Income Before Taxes
0.92

Net Income
0.72

Diluted Normalized EPS
1.02

Period
2019

Total Revenue
49.42

Selling/ General/ Admin Expenses Total
6.49

Depreciation/ Amortization
0.64

Other Operating Expenses Total
15.53

Total Operating Expense
47.97

Operating Income
1.46

Net Income Before Taxes
1.02

Net Income
0.67

Diluted Normalized EPS
0.95

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Sandu Pharmaceuticals Technical

Moving Average SMA

5 Day50.34
10 Day50.51
20 Day51.32

50 Day52.08
100 Day51.72
300 Day54.84

Sandu Pharmaceuticals Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Deccan Health Care
20.3
0.83
4.26
39.1
16
47.48

Crestchem
168.9
0.2
0.12
350
119.7
49.84

Sandu Pharmaceuticals
49.8
-0.41
-0.82
69.5
43.75
48.18

Roopa Industries
58.88
1.39
2.42
114.9
47.26
46.47

Chandra Bhagat Pharma
52.3
-5.7
-9.83
90
46.15
39.46

Sandu Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

28-May-25
Audited Results & Final Dividend

13-Feb-25
Quarterly Results

14-Nov-24
Quarterly Results

12-Aug-24
Quarterly Results & Final Dividend

05-Jun-24
Audited Results

30-May-24
Audited Results

30-Mar-24
Others

14-Feb-24
Quarterly Results

13-Nov-23
Quarterly Results

14-Aug-23
Quarterly Results & Final Dividend

Meeting Date
Announced on
Purpose

30-Sept-24
14-Aug-24
AGM

30-Sept-23
14-Aug-23
AGM

Announced on
Record Date
Ex-Dividend
Dividend Value

28-May-25
-
-
0.8

14-Aug-24
-
19-Sept-24
0.8

14-Aug-23
-
18-Sept-23
0.75

12-Aug-22
-
23-Sept-22
0.75

16-Aug-21
-
22-Sept-21
0.5

View All

Company Profile

ABOUT Sandu Pharmaceuticals

Industry Biotechnology & Drugs
ISIN INE751D01014
BSE Code 524703

Sandu Pharmaceuticals Limited is an India-based company, which is mainly engaged in the business of manufacturing and trading of ayurvedic medicines under the brand name, SANDU. The Company's product category includes digestive health, immunity, muscle and bone health, respiratory health, wellness, and others. Its digestive health products focus on constipation, hyperacidity, indigestion and flatulence, and loose motions, among others. Its wellness products cover female wellness, male wellness and mother and child. Its respiratory health products focus on respiratory health, asthma, and cold and cough. Its ayurveda category includes herbs, panchakarma, dincharya, rutucharya, ahar vihar, arogyadarshika, prakruti and yoga. The Company also offers products, such as an immunity kit and a power herbs range. Its products are manufactured using in-house know-how supplied by Sandu Brothers Private Limited. The Company's products are sold through e-commerce marketplaces.

MANAGEMENT

Vijay Kajrekar Chief Financial Officer
Pratika Mhambray Compliance Officer, Company Secretary
Umesh Sandu Managing Director, Executive Director

SANDU PHARMACEUTICALS SUMMARY

Sandu Pharmaceuticals is trading 0.82% lower at Rs 49.80 as compared to its last closing price. Sandu Pharmaceuticals has been trading in the price range of 51.50 & 49.60. Sandu Pharmaceuticals has given -12.71% in this year & -1.03% in the last 5 days.

Sandu Pharmaceuticals has TTM P/E ratio 14.73 as compared to the sector P/E of 45.09.

The company posted a net profit of 0.33 Crores in its last quarter.

Listed peers of Sandu Pharmaceuticals include Deccan Health Care (4.26%), Crestchem (0.12%), Sandu Pharmaceuticals (-0.82%) etc.

Sandu Pharmaceuticals has a 42.9% promoter holding & 57.1% public holding.

FAQs about Sandu Pharmaceuticals

Sandu Pharmaceuticals is trading at 49.80 as on 27 Jun, 2025 3:29:31 PM. This is -0.82% lower as compared to its previous closing price of 50.21

The market capitalization of Sandu Pharmaceuticals is 48.18 Cr as on 27 Jun, 2025 3:29:31 PM.

The 52 wk high for Sandu Pharmaceuticals is 69.50 whereas the 52 wk low is 43.75

Sandu Pharmaceuticals can be analyzed on the following key metrics -

TTM P/E: 14.73
Sector P/E: 45.09
Dividend Yield: 1.6%
D/E ratio: -

Sandu Pharmaceuticals reported a net profit of 1.55 Cr in 2025.

Sandu Pharmaceuticals Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Sandu Pharmaceuticals Share Price

Price Range

Key Metrics

Sandu Pharmaceuticals Analysis

Sandu Pharmaceuticals Financials

Forecast

Forecast

Forecast

Sandu Pharmaceuticals Technical

Sandu Pharmaceuticals Peers

Sandu Pharmaceuticals Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Sandu Pharmaceuticals

MANAGEMENT

SANDU PHARMACEUTICALS SUMMARY

FAQs about Sandu Pharmaceuticals

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue